| |
| |
|
| Insider
Information: |
Coles N Anthony |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
1,005,229 |
|
|
Indirect Shares
|
124,745 |
|
|
| Direct
Value |
$39,019,319 |
|
|
|
Indirect Value
|
$5,215,846 |
|
|
| Total
Shares |
1,129,974 |
|
|
| Total
Value |
$44,235,164 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -2.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
SVP, Comm. Ops. |
2005-02-03 |
74,540 |
2005-02-03 |
2,076 |
Premium* |
|
|
NPS Pharmaceuticals Inc |
NPSP |
President, COO & Direc... |
2008-03-17 |
220,066 |
2007-01-31 |
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
Chairman & CEO, Director |
2013-10-01 |
0 |
2008-03-31 |
0 |
Premium* |
|
|
Laboratory Corp of America |
LH |
Director |
2013-02-15 |
2,584 |
2011-01-03 |
0 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
Director |
2016-10-24 |
0 |
2016-10-24 |
70,000 |
Premium* |
|
|
McKesson Corp |
MCK |
Director |
2020-08-17 |
0 |
2018-07-25 |
0 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2024-01-02 |
1,393 |
2019-01-02 |
0 |
Premium* |
|
|
Kineta Ord Shs |
KA |
Executive Chair, Direc... |
2021-02-01 |
691,008 |
2021-02-01 |
52,669 |
Premium* |
|
|
Cerevel Therapeutics Holdings, I... |
CERE |
|
2024-06-03 |
15,638 |
2022-12-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
117 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
1,093 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
1,258 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
1,393 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2024-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,440 |
18,144 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Comm. Ops. |
• – – |
2004-03-17 |
4 |
A |
$0.01 |
$19 |
D/D |
1,920 |
3,840 |
|
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Comm. Ops. |
• – – |
2005-02-03 |
4 |
A |
$0.01 |
$57 |
D/D |
5,700 |
74,540 |
|
- |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2023-11-08 |
4 |
OE |
$3.50 |
$350 |
D/D |
100 |
2,804 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Comm. Ops. |
• – – |
2004-05-06 |
4 |
A |
$0.01 |
$650 |
D/D |
65,000 |
68,840 |
|
- |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2023-11-08 |
4 |
AS |
$25.16 |
$2,516 |
D/D |
(100) |
2,704 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2020-11-13 |
4 |
OE |
$345.47 |
$3,800 |
D/D |
11 |
654 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-03-03 |
4 |
OE |
$3.50 |
$10,500 |
D/D |
3,000 |
5,704 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
CEO, President and Director |
• • – |
2007-01-31 |
4 |
A |
$3.22 |
$25,052 |
D/D |
7,780 |
7,780 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, COO & Director |
• • – |
2008-01-11 |
4 |
D |
$3.87 |
$35,999 |
D/D |
(9,302) |
69,317 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
• • – |
2010-04-20 |
4 |
AS |
$29.94 |
$47,201 |
D/D |
(1,576) |
82,566 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2023-11-14 |
4 |
OE |
$3.50 |
$79,884 |
D/D |
22,824 |
25,528 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-03-03 |
4 |
AS |
$27.19 |
$81,570 |
D/D |
(3,000) |
2,704 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2023-11-07 |
4 |
OE |
$3.50 |
$94,766 |
D/D |
27,076 |
29,780 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2024-02-07 |
4 |
S |
$41.54 |
$104,110 |
D/D |
(2,506) |
15,638 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2023-11-02 |
4 |
OE |
$3.50 |
$135,097 |
D/D |
38,599 |
41,303 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-03-02 |
4 |
OE |
$3.50 |
$164,500 |
D/D |
47,000 |
49,704 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
• • – |
2009-04-01 |
4 |
AS |
$27.55 |
$170,402 |
D/D |
(6,109) |
68,891 |
0 |
- |
|
| MCK |
McKesson Corp |
Director |
– • – |
2018-08-31 |
4 |
AS |
$128.69 |
$173,732 |
D/D |
(1,350) |
0 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2022-12-09 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-02-07 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-04-11 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
0 |
- |
|
117 Records found
|
|
Page 2 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
